Continuous biopharmaceutical manufacturing is on a trajectory for significant growth, projected to expand by 17% by 2033. This increase stems from its ability to enhance production efficiency, improve product quality, and substantially reduce costs when compared to traditional batch processing methods. Manufacturers can adopt either a fully continuous model or a hybrid approach, which allows for gradual integration of continuous processes alongside traditional methods.
Enzene’s Innovative Approach
Enzene, a forward-thinking contract development and manufacturing organization (CDMO), is among the pioneers in implementing fully connected continuous manufacturing (FCCM™) technology. This modular approach empowers manufacturers to transition towards a fully continuous production model step by step. By enabling the automation and interlinking of various process sections, Enzene allows for a seamless transition while maintaining certain traditional processes.
According to Himanshu Gadgil, PhD, CEO of Enzene, the goal is clear: “By 2025, we target monoclonal antibody (mAb) production costs of less than $40 per gram.” This ambitious target is a stark contrast to the current landscape, where other continuous processing methods range between $80 to $100 per gram, and fed-batch processes can cost anywhere from $150 to $300 per gram.
EnzeneX™: A Game-Changer
Enzene’s flagship platform, EnzeneX™, powered by FCCM technology, has garnered significant recognition, including the 2025 CPHI Pharma Award for Manufacturing Excellence. This platform is deemed the first fully connected continuous manufacturing technology validated for commercial biologics applications. To date, four mAbs have been successfully commercialized using this innovative technology, with pertuzumab being the most recent addition.
The modular nature of EnzeneX™ allows it to function as a semi-continuous hybrid system, where specific elements can operate continuously while others remain separate. This flexibility aids in retrofitting continuous components into existing batch processes, thereby enhancing overall efficiency.
Enhanced Efficiency and Cost Savings
Gadgil emphasizes the advantages of the fully connected platform, stating, “The system is designed to operate continuously from bioreactor to pre-drug substance, maximizing yield and efficiency.” The yield produced through this method is tenfold greater than conventional batch processes, leading to cost savings of 40 to 50% for complex molecules.
Traditionally, biologics manufacturing involves multiple large bioreactors operating sequentially, often requiring up to six massive tanks. This consumes significant space and resources, increasing operational risks. In contrast, FCCM technology continuously feeds fresh media into cell cultures, effectively linking reaction, separation, and purification into a single streamlined process.
Smaller Footprint, Larger Impact
The footprint of FCCM technology is reported to be 70% smaller than that of comparable batch processes. This compact design, along with the ability to utilize smaller cleanroom spaces, results in a reduced carbon footprint per gram of protein produced. Such advancements not only benefit manufacturers but also contribute positively to environmental sustainability.
Enzene’s journey began in Pune, India, in 2015 as a clone-to-formulation and clinical manufacturing facility. By 2020, in response to the COVID-19 pandemic, the company expanded its operations to include CDMO capabilities, focusing on early-stage biologics manufacturing for U.S.-based clients.
Expanding U.S. Operations
The establishment of a U.S. facility in New Jersey, which spans 80,000 square feet, marks a significant milestone for Enzene. This manufacturing center not only features the EnzeneX platform but also positions the company to meet the growing demand for biologics in the U.S. market.
As Gadgil notes, “With our operations now established in the U.S., we aim to anchor our business and significantly expand our manufacturing capacity in the coming years.” This expansion aligns with the increasing need for localized manufacturing solutions to mitigate supply chain complexities.
Supporting Diverse Client Needs
Enzene prides itself on collaborating with clients of various sizes. While larger CDMOs often cater to big pharma, Enzene recognizes the challenges early-stage companies face in finding suitable partners. By offering rapid onboarding and modular solutions, Enzene effectively bridges this gap, providing tailored support from early-stage supply to commercialization.
Moreover, interest from major pharmaceutical companies is on the rise. Discussions are underway with several top ten pharma firms, highlighting the flexibility and efficiency of Enzene’s platform, which is appealing to both emerging and established entities in the industry.
Opportunities in Animal Health
Enzene has also ventured into manufacturing therapeutics for both human and animal health markets. This diversification is seen as a logical extension of their core capabilities. The animal health market is considered to be at a similar maturity level to human biotherapeutics from a decade ago, presenting substantial opportunities for growth through modern bioprocessing technologies.
Miller reiterates that the innovative concepts and deep expertise that Enzene embodies can be applied effectively to the animal health sector. The current gap between market demand and manufacturing infrastructure for animal health products signifies a ripe opportunity for leveraging advanced bioprocessing techniques.
A Commitment to Ongoing Innovation
Despite recent expansions, Enzene remains committed to continuous improvement and innovation. “We are not content to stand still,” Gadgil asserts. The company is actively working on a new generation of the EnzeneX platform, emphasizing that the achievements in cost and efficiency are not merely one-time successes but are built into the platform’s design for scalability.
Conclusion
In summary, Enzene’s strategic innovations in continuous bioprocessing are revolutionizing mAb production. By enhancing efficiency, reducing costs, and promoting sustainability, the company positions itself as a leader in the biopharmaceutical manufacturing landscape. Enzene’s commitment to ongoing development ensures that it remains at the forefront of this dynamic industry, ready to meet the evolving needs of its diverse clients.
- Continuous biopharmaceutical manufacturing is set to grow by 17% by 2033.
- EnzeneX™ platform enables significant cost reductions in mAb production.
- FCCM technology offers a modular approach to integrate continuous processes.
- Enzene is expanding its U.S. operations to meet growing market demands.
- The company is exploring opportunities in both human and animal health markets.
Read more → www.genengnews.com